Novel small-molecule inhibitors of the vascular endothelial growth factor receptor

Clinical Lung Cancer

Volumn 8, Issue SUPPL. 2, 2007, Pages

  Adjei, Alex A ^a  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

Author keywords

AMG 706; Axitinib; Cediranib; Kinase inhibitors; Pazopanib; XL647

Indexed keywords

AXITINIB; CARBOPLATIN; CEDIRANIB; DOCETAXEL; EPIDERMAL GROWTH FACTOR RECEPTOR 2; FLT3 LIGAND; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; N (3,3 DIMETHYL 6 INDOLINYL) 2 (4 PYRIDINYLMETHYLAMINO)NICOTINAMIDE; OXALIPLATIN; PACLITAXEL; PANITUMUMAB; PAZOPANIB; PEMETREXED; PLATELET DERIVED GROWTH FACTOR BETA RECEPTOR; PROTEIN RET; SORAFENIB; STEM CELL FACTOR RECEPTOR; SUNITINIB; UNCLASSIFIED DRUG; VANDETANIB; VASCULOTROPIN INHIBITOR; VASCULOTROPIN RECEPTOR; VATALANIB; XL 647;

ANOREXIA; ASTHENIA; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER COMBINATION CHEMOTHERAPY; CANCER FATIGUE; CANCER INVASION; CLINICAL TRIAL; COMBINATION CHEMOTHERAPY; CONSTIPATION; DIARRHEA; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG INHIBITION; DRUG SYNTHESIS; DRUG TOLERABILITY; DYSPNEA; GASTROINTESTINAL STROMAL TUMOR; HAND FOOT SYNDROME; HEADACHE; HEMOPTYSIS; HUMAN; HYPERTENSION; KIDNEY CARCINOMA; LUNG NON SMALL CELL CANCER; MELANOMA; MULTIPLE CYCLE TREATMENT; NAUSEA; PROTEIN EXPRESSION; PROTEINURIA; RASH; REVIEW; THYROID CANCER; VOMITING;

EID: 34147186711     PISSN: 15257304     EISSN: None     Source Type: Journal    
DOI: 10.3816/CLC.2007.s.005     Document Type: Article

References (39)

1. Senger DR, Galli SJ, Dvorak AM, et al. Tumor cells secrete a vascular permeability factor that promotes accumulation of ascites fluid. Science 1983; 219:983-985.
2. Ferrara N, Henzel WJ. Pituitary follicular cells secrete a novel heparin-binding growth factor specific for vascular endothelial cells. Biochem Biophys Res Commun 1989; 161:851-858.
3. Connolly DT, Olander JV, Heuvelman D, et al. Human vascular permeability factor. Isolation from U937 cells. J Biol Chem 1989; 264:20017-20024.
4. Ferrara N, Houck KA, Jakeman LB, et al. The vascular endothelial growth factor family of polypeptides. J Cell Biochem 1991; 47:211-218.
5. Folkman J. Angiogenesis inhibitors generated by tumors. Mol Med 1995; 1:120-122.
6. Montironi R, Diamanti L, Thompson D, et al. Analysis of the capillary architecture in the precursors of prostate cancer: recent findings and new concepts. Eur Urol 1996; 30:191-200.
7. Singh RK, Fidler IJ. Regulation of tumor angiogenesis by organ-specific cytokines. Curr Top Microbiol Immunol 1996; 213:1-11.
8. Ellis LM, Fidler IJ. Angiogenesis and metastasis. Eur J Cancer 1996; 32A:2451-2460.
9. Breslin JW, Pappas PJ, Cerveira JJ, et al. VEGF increases endothelial permeability by separate signaling pathways involving ERK-1/2 and nitric oxide. Am J Physiol Heart Circ Physiol 2003; 284:H92-H100.
10. Shibuya M, Yamaguchi S, Yamane A, et al. Nucleotide sequence and expression of a novel human receptor-type tyrosine kinase gene (flt) closely related to the fms family. Oncogene 1990; 5:519-524.
11. Terman BI, Dougher-Vermazen M, Carrion ME, et al. Identification of the KDR tyrosine kinase as a receptor for vascular endothelial cell growth factor. Biochem Biophys Res Commun 1992; 187:1579-1586.
12. Brown LF, Berse B, Jackman RW, et al. Expression of vascular permeability factor (vascular endothelial growth factor) and its receptors in adenocarcinomas of the gastrointestinal tract. Cancer Res 1993; 53:4727-4735.
13. Paz K, Zhu Z. Development of angiogenesis inhibitors to vascular endothelial growth factor receptor 2. Current status and future perspective. Frontier Biosci 2005; 10:1415-1439.
14. Dvorak HF. Vascular permeability factor/vascular endothelial growth factor: critical cytokine in tumor angiogenesis and a potential target for diagnosis and therapy. J Clin Oncol 2002; 20:4368-4380.
15. Hicklin DJ, Ellis LM. Role of the vascular endothelial growth factor pathway in tumor growth and angiogenesis. J Clin Oncol 2005; 23:1011-1027.
16. Karpanen T, Alitalo K. Lymphatic vessels as targers of tumor therapy? J Exp Med 2001; 194:F37-F42.
17. Valtola R, Salven P, Heikkila P, et al. VEGFR-3 and its ligand VEGF-C are associated with angiogenesis in breast cancer. Am J Pathol 1999; 154:1381-1390.
18. Partanen TA, Alitalo K, Miettinen M. Lack of lymphatic vascular specificity of vascular endothelial growth factor receptor 3 in 185 vascular tumors. Cancer 1999; 86:2406-2412.
19. Ferrara N, Gerber HP, LeCouter J. The biology of VEGF and its receptors. Nat Med 2003; 9:669-676.
20. Dy GK, Adjei AA. Angiogenesis inhibitors in lung cancer: a promise fulfilled. Clin Lung Cancer 2006; 7(suppl 4):S145-149.
21. Herbst RS, Onn A, Sandler A. Angiogenesis and lung cancer: prognostic and therapeutic implications. J Clin Oncol 2005; 23:3243-3256.
22. Inai T, Mancuso M, Hashizume H, et al. Inhibition of vascular endothelial growth factor (VEGF) signaling in cancer causes loss of endothelial fenestrations, regression of tumor vessels, and appearance of basement membrane ghosts. Am J Pathol 2004; 165:35-52.
23. Rugo HS, Herbst RS, Liu G, et al. Phase I trial of the oral antiangiogenesis agent AG-013736 in patients with advanced solid tumors: pharmacokinetic and clinical results. J Clin Oncol 2005; 23:5474-5483.
24. Rini B, Rixe O, Bukowski R, et al. AG-013736, a multi-target tyrosine kinase receptor inhibitor, demonstrates anti-tumor activity in a phase 2 study of cytokine-refractory, metastatic renal cell cancer (RCC). J Clin Oncol 2005; 23:380s (Abstract #4509).
25. Wedge SR, Kendrew J, Hennequin LF, et al. AZD2171: a highly potent, orally bioavailable, vascular endothelial growth factor receptor-2 tyrosine kinase inhibitor for the treatment of cancer. Cancer Res 2005; 65:4389-4400.
26. Drevs J, Medinger M, Mross K, et al. Phase I clinical evaluation of AZD2171, a highly potent VEGF receptor tyrosine kinase inhibitor, in patients with advanced tumors. J Clin Oncol 2005; 23(16 suppl):192s (Abstract #3002).
27. Lorusso PM, Heath E, Valdivieso M, et al. Phase I evaluation of AZD2171, a highly potent and selective inhibitor of VEGFR signaling, in combination with selected chemotherapy regimens in patients with advanced solid tumors. J Clin Oncol 2006; 24(18 suppl):129s (Abstract #3034).
28. Podar K, Tonon G, Abtahi D, et al. In vitro and in vivo activity of the VEGF receptor inhibitor pazopanib (GW786034) in Multiple Myeloma: therapeutic implications. Proc Am Assoc Cancer Res 2006; 47:?? (Abstract #5658).
29. Hurwitz H, Dowlati A, Savage S, et al. Tolerability and pharmacokinetics of oral administration of GW786034 in pts with solid tumors. J Clin Oncol 2005; 23(16 suppl):195s (Abstract #3012).
30. Suttle AB, Hurwitz H, Dowlati A, et al. Pharmacokinetics (PK) and tolerability of GW786034, a VEGFR tyrosine kinase inhibitor, after daily oral administration to patients with solid tumors. J Clin Oncol 2004; 22(14 suppl):208 (Abstract #3054).
31. An open-label, dose-finding study to evaluate the safety and pharmacokinetics (PK) of AMG 706 with carboplatin/paclitaxel, AMG 706 with panitumumab and AMG 706 with panitumumab and carboplatin/paclitaxel in the treatment of subjects with advanced non-small cell lung cancer (NSCLC). Amgen. Available at: http://clinicaltrials.gov/ct/show/NCT00094835?order=1. Accessed: November 26, 2006.
32. Sikic BJ, Wakelee HA, Adjei AA, et al. A phase I dose-escalation and pharmacokinetic study of XL647, a novel spectrum selective kinase inhibitor administered orally to patients with advanced solid malignancies. Eur J Cancer 2006; 4(suppl 12):35 (Abstract #??)
33. Halaban R, Moellman G. White mutants in mice shedding light on humans. J Invest Dermatol 1993; 100(2 suppl):176S-185S.
34. Tsatsaris V, Goffin F, Munaut C, et al. Overexpression of the soluble vascular endothelial growth factor receptor in preeclamptic patients: pathophysiological consequences. J Clin Endocrinol Metab 2003; 88:5555-5563.
35. McKeeman GC, Ardill JE, Caldwell CM, et al. Soluble vascular endothelial growth factor receptor-1 (sFlt-1) is increased throughout gestation in patients who have preeclampsia develop. Am J Obstet Gynecol 2004; 191:1240-1246.
36. Glusker P, Recht L, Lane B. Reversible posterior leukoencephalopathy syndrome and bevacizumab. N Engl J Med 2006; 354:980-982.
37. Cines DB, Pollak ES, Buck CA, et al. Endothelial cells in physiology and in the pathophysiology of vascular disorders. Blood 1998; 91:3527-3561.
38. Pinedo HM. The role of VEGF in oncology: effects on hemostatic and thrombosis. Pathophysiol Haemost Thromb 2003; 33(suppl 1):11-12.
39. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N Engl J Med 2004; 350:2335-2342.